Financial PerformanceKrystal Biotech's strong financial foundation is highlighted by its robust cash position, providing a solid base for future operations and investments.
Gene Therapy AdvancementsKrystal Biotech's HSV-1 gene therapy vector shows promise for posterior eye delivery, offering an innovative avenue for further therapeutic developments.
Pipeline PotentialKrystal Biotech expects to deliver data readouts showcasing the breadth and potential of its proprietary HSV-1 based gene delivery platform, signaling future growth and expansion into new therapeutic areas.